ACE2 News and Research

RSS

Impact of SARS-CoV-2 Omicron mutations on the use of therapeutic antibodies in COVID-19 treatment

Researchers investigated the mutations reported in the Omicron variant and its likely impact on the use of therapeutic antibodies in COVID-19 treatment as well as on vaccinated individuals.

17 Dec 2021

Investigating SARS-CoV-2 genomics-informed outbreaks using new bioinformatics tools

Researchers have created a tool designed to make as much use of the overwhelming amount of SARS-CoV-2 data as possible.

17 Dec 2021

Analysis of the alteration of neutralizing titers with Omicron pseudovirus

A new study measured antibody levels from blood samples of vaccinated individuals and individuals who recovered from COVID-19 illness.

17 Dec 2021

Comparison of RBD/ACE2 receptor complex in wild type SARS-CoV-2 and Omicron variant

New research details the molecular landscape of Omicron’s RBD and how it differs from the original SARS-CoV-2 strain.

17 Dec 2021

New study demonstrates SARS-CoV-2 Omicron antibody escape

A new study examined the neutralization of virus variants using three sets of antibodies: serum from individuals vaccinated or infected with earlier variants of the virus; concentrated human antibodies from plasma donors; and approved monoclonal antibodies.

16 Dec 2021

Therapeutic antibodies deemed ineffective against Omicron variant of SARS-CoV-2

A new study found that the Omicron S protein evades antibodies with a 44-fold higher efficiency than the Delta variant's spike, rendering therapeutic antibodies ineffective and likely negatively impacting antibody protection induced by infection or double vaccination.

16 Dec 2021

Neutralization potency of COVID-19 vaccine boosters against SARS-CoV-2 variant pseudoviruses

A new study has used this assay to evaluate sera, obtained from 239 individuals vaccinated via any of the above-stated vaccines against SARS-CoV-2’s original strain, the Delta, and Omicron SARS-CoV-2 pseudoviruses.

16 Dec 2021

Human monoclonal antibody protects against SARS-CoV-2 and SARS-CoV in vivo

Scientists identified a human monoclonal antibody (mAb), which successfully neutralized or bound all sarbecoviruses tested in vitro.

16 Dec 2021

Evaluation of SARS-CoV-2 neutralizing antibodies in mothers and infants

A new study assessed nAb activities against five strains of SARS-CoV-2 in paired maternal and infant cord blood samples.

15 Dec 2021

How SARS-CoV-2 affects the male reproductive system

Researchers review the potentially harmful consequences on the male reproductive system in COVID-19 patients.

15 Dec 2021

SARS-CoV-2 VOCs dependent on IFITM2 for efficient infection establishment

Researchers demonstrate that the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 require endogenous IFITM2 expression for efficient replication.

15 Dec 2021

Receptor binding of SARS-CoV-2 Omicron variant compared to other variants

Researchers compared the binding of the new SARS-CoV-2 VOC Omicron’s RBD and ACE2 receptor with the original Wuhan SARS-CoV-2 strain and other VOCs such as Beta and Delta.

15 Dec 2021

SARS-CoV-2 Omicron variant binding to its receptor and therapeutic entities

Researchers generated a set of computed structural models of the Omicron receptor-binding domain attached to its receptor angiotensin-converting enzyme.

15 Dec 2021

Structure of human receptor and Omicron variant

Researchers studied the complex structure of the receptor-binding domain of the omicron variant with the human host receptor angiotensin-converting enzyme 2.

15 Dec 2021

Omicron evades immunity more than other SARS-CoV-2 variants

Researchers find that the SARS-CoV-2 Omicron variant shows a much more extensive escape from vaccine-elicited immunity.

14 Dec 2021

"Supermere" discovery may offer clues to earlier diagnoses and treatment of several diseases

Researchers at Vanderbilt University Medical Center have discovered a nanoparticle released from cells, called a "supermere," which contains enzymes, proteins and RNA associated with multiple cancers, cardiovascular disease, Alzheimer's disease and even COVID-19.

14 Dec 2021

Machine learning method for determining impact of mutations in the SARS-CoV-2 RBD on binding and antibody escape

Deep mutational learning (DML) is a technique developed by researchers from multiple institutions that combines experimental yeast display screening of RBD mutagenesis libraries with deep sequencing and machine learning.

14 Dec 2021

Omicron variant may strike double vaccinated

Largely, scientists are skeptical that the Omicron variant can infect vaccinated individuals. However, a new study published on the medRxiv* preprint server has conducted neutralization assays using an Omicron isolate obtained from patients residing in the United Kingdom.

13 Dec 2021

Iota-carrageenan inhibits replication of SARS-CoV-2 VOCs

Scientists have recently reported the efficacy of carrageenan against both the SARS-CoV-2 original strain as well as the Alpha, Beta, Gamma, and Delta VOCs.

13 Dec 2021

Glycans strengthen interaction between viral spike proteins and ACE2 receptors on host cells

A new study shows that the ACE2 and RBD of coronavirus spike fragments have different binding strengths and dissociation rates when they are glycosylated and non-glycosylated.

13 Dec 2021